The positive interim data from the Phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel for treating metastatic pancreatic cancer is a significant milestone for Actuate Therapeutics. This development could lead to increased investor confidence and a potential rise in ACTU's stock price, as successful trial results are crucial for biopharmaceutical companies.